Government
Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.
As part of the agreement, Phlow will help build the United States’ first Strategic Active Pharmaceutical Ingredients Reserve, a long-term, national stockpile to secure key ingredients used to manufacture the most essential medicines in the United States.
Research conducted under the collaboration will support FDA objectives to explore the natural history of the disease, as well as treatment and diagnostic patterns through the use of relevant and new data sources.
Expected to launch in June or July, the study plans to test as many as 325,000 people to learn how the SARS-CoV-2 virus is spreading nationally, according to Reuters, reporting before the official announcement.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
The approval was based on interim analysis from the company’s Phase III IMpower110 trial.
With the new approval, Rubraca becomes the first PARP inhibitor approved in a prostate cancer setting.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
Earlier this week, Sanofi’s chief executive officer Paul Hudson indicated that the U.S. would have first access to its COVID-19 vaccine because of the significant financial support it is receiving from the U.S. government.
PRESS RELEASES